Alpha 2.0
Login Register
» Authors » Donato Natale

Donato Natale

Explore the profile of Donato Natale including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 197
Followers 0
Related Specialties
Oncology
Gastroenterology
Hematology
Top 10 Co-Authors
Bruno Massidda
Luigi Maiorino
Pasquale Comella
Francesco Perrone
Gianfranco Filippelli
Sandro Pignata
Enrico Breda
Salvatore Tafuto
Antonio Farris
Giovanni Scambia
Published In
Clin Colorectal Cancer
J Clin Oncol
Oncotarget
Suppl Tumori
J Cancer Res Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment
Giordano G, Milella M, Landriscina M, Bergamo F, Tirino G, Santaniello A, et al.
Cancer Med . 2024 Jun; 13(12):e7345. PMID: 38924262
Background: Pancreatic cancer (PC) first-line therapy often consists of polychemotherapy regimens, but choosing a second-line therapy after disease progression, especially following first-line FOLFIRINOX, remains a clinical challenge. This study presents...
2.
Predictive factors for 6 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer
Formica V, Ionta M, Massidda B, Vessia G, Maiorino L, Casaretti R, et al.
Oncotarget . 2018 Feb; 9(2):2876-2886. PMID: 29416820
Early switching to de-intensified maintenance regimen is still a matter of debate in metastatic colorectal cancer (mCRC). The MARTHA trial, a S.I.C.O.G. phase III randomized trial, compared FOLOFIRI+bevacizumab (B) for...
3.
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study
Pignata S, Scambia G, Bologna A, Signoriello S, Vergote I, Wagner U, et al.
J Clin Oncol . 2017 Aug; 35(29):3347-3353. PMID: 28825853
Purpose Platinum-based chemotherapy (PBC) for patients with progressing ovarian cancer (OC) is more effective with a longer time interval from previous platinum treatment (platinum-free interval [PFI]). In 1999, it was...
4.
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
Perrone F, Baldassarre G, Indraccolo S, Signoriello S, Chiappetta G, Esposito F, et al.
Oncotarget . 2016 Sep; 7(45):72654-72661. PMID: 27655643
Background: No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2...
5.
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial
Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al.
J Clin Oncol . 2011 Aug; 29(27):3628-35. PMID: 21844495
Purpose: Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal...
6.
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience
Comella P, Massidda B, Natale D, Putzu C, Sandomenico C, Filippelli G, et al.
Clin Colorectal Cancer . 2011 May; 10(1):42-7. PMID: 21609935
Background: We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC). Here, we report on the safety and activity...
7.
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401
Comella P, Massidda B, Filippelli G, Farris A, Natale D, Barberis G, et al.
J Cancer Res Clin Oncol . 2008 Aug; 135(2):217-26. PMID: 18719941
Purpose: Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients. We aimed at comparing these two regimens in terms of response...
8.
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients
Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, et al.
Leuk Lymphoma . 2007 Feb; 48(1):56-64. PMID: 17325848
Over a period of 28 months, we observed five cases of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates (BP) at our institution. This prompted us to...
9.
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial
Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, et al.
BMC Cancer . 2006 Aug; 6:202. PMID: 16882344
Background: The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of...
10.
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials
Comella P, Massidda B, Filippelli G, Natale D, Farris A, Buzzi F, et al.
Clin Colorectal Cancer . 2005 Oct; 5(3):203-10. PMID: 16197624
Background: A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in...